

## MK-0616

## PCSK9

oral macrocyclic peptide inhibitor of PCSK9
Ph. III for hypercholesterolemia planned 2H 2023
from mRNA display + SBDD
J. Am. Coll. Cardiol., April 25, 2023

MERCK, RAHWAY, NJ


## camlipixant

P2X3
oral BID P2X3 receptor antagonist
Ph. Ill for first-line treatment of refractory chronic cough
non-competitive homotrimeric receptor antagonist; discovery not disclosed

GSK acquisition announcement, April 18, 2023
ASTRAZENECA/NEOMED/BELLUS HEALTH/GSK


## RMC-6291

KRAS $^{\text {G12C }}$
oral KRAS ${ }^{612 C}(O N)$ tri-complex inhibitor
Ph. I/lb for adv. solid tumors
from FBDD + SBDD
AACR, April 2023
REVOLUTION MEDICINES, REDWOOD CITY, CA


BAY-747
sGC
oral QD sGC stimulator
Ph . I in healthy volunteers completed
from HTS + optimization
J. Med. Chem., April 11, 2023

BAYER, WUPPERTAL, DE


## gepotidacin

bacterial topoisomerase
oral BID antibacterial Type II topoisomerase inhibitor Ph. III for uncomplicated UTIs
from unbiased antibacterial screen + opt.
ECCMID, April 2023
GLAXO (GSK), STEVENAGE, UK


## CFT1946

BRAFV600X
oral mutant-selective BRAFV600X degrader
Ph.I for BRAF-driven cancers
from CRBN-based E3 recruiter + vemurafenib
AACR, April 2023
C4 THERAPEUTICS, WATERTOWN, MA


IOA-244 (roginolisib)
PI3Kd
oral QD non-competitive PI3Kd inhibitor
Ph. I in metastatic cancers
from focused kinase inhibitor screen ( 60 K cmpds ) + opt.
Cancer Res. Commun., April 14, 2023
MERCK SERONO / IONCTURA, CH


## difamilast

PDE4B
topical PDE4 inhibitor
marketed in Japan
PDE4B subtype-selective inhibitor; discovery not disclosed
JPET, April 11, 2023
OTSUKA, TOKYO, JP


ARV-766
AR
oral AR-degrading PROTAC
Ph. Il for adv. prostate cancer
from CRBN-based E3 recruiter + AR ligand
AACR, April 2023
ARVINAS, NEW HAVEN, CT


## navoximod

IDO
oral IDO1 inhibitor
Ph. I completed ( $50-800 \mathrm{mg}$ ) for cancer
from phenylimidazole + SBDD
JPET, April 14, 2023
NEWLINK GENETICS / GENENTECH

